| Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies GY Ho, N Woodward, JIG Coward Critical reviews in oncology/hematology 102, 37-46, 2016 | 301 | 2016 |
| Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab JL Hare, JK Brown, R Leano, C Jenkins, N Woodward, TH Marwick American heart journal 158 (2), 294-301, 2009 | 278 | 2009 |
| Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab, ... Annals of Oncology 31 (11), 1526-1535, 2020 | 264 | 2020 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 171 | 2022 |
| Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma KM Field, J Simes, AK Nowak, L Cher, H Wheeler, EJ Hovey, CSB Brown, ... Neuro-oncology 17 (11), 1504-1513, 2015 | 149 | 2015 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early breast cancer: a systematic review and meta-analysis K Roberts, K Rickett, R Greer, N Woodward Critical Reviews in Oncology/Hematology 111, 66-80, 2017 | 69 | 2017 |
| Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer KE Roberts, K Rickett, S Feng, D Vagenas, NE Woodward Cochrane Database of Systematic Reviews, 2020 | 48 | 2020 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 46 | 2021 |
| Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician’s choice standard-of-care chemotherapy HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, L Fehrenbacher, ... JNCI cancer spectrum 4 (1), pkz085, 2020 | 27 | 2020 |
| Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report TP Moloney, W Xu, K Rallah-Baker, N Oliveira, N Woodward, JJ Farrah BMC ophthalmology 14, 1-6, 2014 | 21 | 2014 |
| Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b CE Snell, M Gough, C Liu, K Middleton, C Pyke, C Shannon, N Woodward, ... British Journal of Cancer 119 (11), 1316-1325, 2018 | 16 | 2018 |
| Maintaining dose intensity of adjuvant chemotherapy in older patients with breast cancer R Ladwa, T Kalas, S Pathmanathan, N Woodward, D Wyld, ... Clinical breast cancer 18 (5), e1181-e1187, 2018 | 16 | 2018 |
| A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors C Lemech, N Woodward, N Chan, J Mortimer, L Naumovski, ... Investigational New Drugs 38, 1815-1825, 2020 | 14 | 2020 |
| Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen CE Snell, M Gough, K Middleton, M Hsieh, L Furnas, B Seidl, K Gibbons, ... Journal of Clinical Pathology 70 (11), 954-960, 2017 | 13 | 2017 |
| Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer KE Roberts, IT Adsett, K Rickett, SM Conroy, MD Chatfield, NE Woodward Cochrane Database of Systematic Reviews, 2022 | 12 | 2022 |
| Results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2 … N Woodward, RH De Boer, A Redfern, M White, J Young, M Truman, ... Clinical Breast Cancer 19 (3), 216-224, 2019 | 12 | 2019 |
| Hormone receptor positive, HER2 negative metastatic breast cancer: a systematic review of the current treatment landscape J Beith, K Burslem, R Bell, N Woodward, N McCarthy, R De Boer, S Loi, ... Asia‐Pacific Journal of Clinical Oncology 12, 3-18, 2016 | 12 | 2016 |
| Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): final overall survival (OS … JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Goncalves, S Diab, ... Cancer Research 80 (16), 2020 | 9 | 2020 |
| EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy … HS Rugo, J Ettl, NE Woodward, SA Hurvitz, A Goncalves, KH Lee, ... Journal of Clinical Oncology 36 (15_suppl), 1069-1069, 2018 | 8 | 2018 |
